Skip to main content
. 2012 Sep 13;14(4):915–924. doi: 10.1208/s12248-012-9406-x

Table IV.

Changes Made to the Study Design or Formulation to Achieve Successful Pivotal BE Studies of HV Drugs after the Initial BE Studies Failed to Meet the Acceptance Criteria

Change made No. of ANDAs Percent
Increase in sample size in two-way crossover BE study 41 91
Changed to three-way study design and RSABE 3 7
Reformulated 1 2
Total 45 100